A Phase 3 interventional study of Trastuzumab in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 23 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-18.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.
Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 124th largest by enrollment of the 366 interventional ones that give a count, is one of 26 that started in 2013, is one of 60 in phase 3, and was the 203rd registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
SWOG Cancer Research Network · Sites in United States
Ages 18+
Duke University · Sites in United States
Ages 18+ · Women only
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–90
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–70 · Women only
Institut Curie · Sites in France
Ages 18+
By country, each count listing its studies:
Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, trastuzumab is the treatment under test here. Read study by study →
374 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 51 · Phase 2 270 · Phase 3 61 · Phase 4 7
First in 1998; this study’s year is marked. 26 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 102 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 61 across the 366 interventional studies. Of the 235 that completed or were terminated, 128 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
73 of 374 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
229 studies in Breast Neoplasms by Hoffmann-La Roche: 16 open now, 28 under way, 13 of them phase 3. Of 193 finished, 120 (62%) have results posted.
Among the 229 studies in Breast Neoplasms by Hoffmann-La Roche, this one is the 103rd largest by enrollment of the 170 interventional ones that give a count, is one of 11 that started in 2013, is one of 61 in phase 3, and was the 114th registered.
Hoffmann-La Roche’s Breast Neoplasms studies by the year they started, since 1998.
22 of the studies testing trastuzumab in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06035679Youzhi ZhuPyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer | 2026-11-30 |
| NCT05891561Shanghai Jiao Tong University School of MedicineShort-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer | 2026-12 |
| NCT04886531Ruth O'ReganTrial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers | 2026-12-22 |
| NCT07095023Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNeoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer | 2026-12-30 |
| NCT07635342Hebei Medical University Fourth HospitalPyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer | 2026-12-31 |
Add all 22 to your calendar (.ics) → With an account.
Among the 374 studies testing trastuzumab in Breast Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 229 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This single arm, multicenter study will evaluate the safety of assisted subcutaneous administration of trastuzumab in participants with HER2+ eBC. Participants who have completed the first 6 cycles of intravenous (IV) trastuzumab as part of the (neo)adjuvant treatment will be eligible to receive a further 12 cycles of trastuzumab in this study. Participants will receive IV trastuzumab at initial loading dose of 8 milligrams per kilogram (mg/kg) body weight (BW) for three-weekly (q3w) regimen and then recommended maintenance dose of 6 mg/kg BW q3w for the first 3 cycles (cycles 7-9) in hospital followed by subcutaneous (SC) administration of trastuzumab at a fixed dose of 600 mg q3w for next 3 cycles (Cycles 10-12) at hospital and SC administration of trastuzumab at a fixed dose of 600 mg q3w at home for the next 6 cycles (Cycles 13-18).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with HER2+ eBC who completed the first 6 cycles of trastuzumab IV infusion as part of the (neo) adjuvant treatment will be included to continue to receive 12 cycles of trastuzumab to complete a total of 18 cycles of trastuzumab. Participants will receive trastuzumab IV infusion at initial loading dose of 8 mg/kg BW for q3w regimen as a part of neo adjuvant treatment before entering in the study and then recommended maintenance dose of 6 mg/kg BW q3w for the first 3 cycles (cycles 7-9) in hospital followed by SC administration of trastuzumab at a fixed dose of 600 mg q3w for next 3 cycles (Cycles 10-12) at hospital and SC administration of trastuzumab at a fixed dose of 600 mg q3w at home for the next 6 cycles (Cycles 13-18) (Each cycle=21 days).
Drug: Trastuzumab
Health Care Professionals (HCPs) included for polling purposes. HCPs were not enrolled in the study.
Trastuzumab 8 mg/kg (loading dose) and 6 mg/kg (maintenance dose) IV infusion q3w; Trastuzumab 600 mg q3w SC injection will be administered as per the schedule specified in the arm.
Also known as: Herceptin
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs included both serious and non- serious AEs. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. An emergent AE was defined as occurring within 35 days after last treatment administration.
Time frame: Up to 45 months
Number of Participants With Modalities Assessed Using Patient Satisfaction Questionnaire 1 (PSQ1): In-Hospital
PSQ1 is a quality of care questionnaire containing 14 questions each of Sections A and B, with a total of 28 questions categorized on the opinion of participants about the clinicians, opinion of participants about the other staff and other questions. Responses to questions with section A (except question 11) were categorized to "not at all", "to a small extent", "to a moderate extent", "to a large extent", "to a very large extent", "Not applicable" and "missing". Responses to questions with section B were categorized to "Not important", "a little important", "important", "very important", "of utmost importance", "not applicable" and "missing". Responses to question 11 with section A were categorized to "Yes, but not long", "yes, quite long", "yes, much long" and "missing". Participant experience with the treatment provided during the in-hospital part of the study was evaluated with PSQ1 questionnaire completed by the participant prior to the first dose of trastuzumab SC at home.
Time frame: Prior (0 hour) to first trastuzumab SC administration at Cycle 13 (cycle length =21 days)
Number of Participants With Modalities Assessed Using Patient Satisfaction Questionnaire 2 (PSQ2): At Home
PSQ2 is a quality of care questionnaire containing 13 questions each of Sections A and B, with a total of 26 questions categorized on the opinion of participants about the clinicians, opinion of participant about the other staff and other questions. Responses to questions with section A were categorized to "Not at all", "To a small extent", "to a moderate extent", "to a large extent", "to a very large extent", "Not applicable" and "missing". Responses to questions with section B were categorized to "Not important", "a little important", "important", "very important", "of utmost importance", "not applicable" and "missing". Participant experience with the treatment provided during the at-home part of the study was evaluated with the PSQ2 questionnaire completed by the participant prior to the fifth dose of trastuzumab SC at home.
Time frame: Prior (0 hour) to fifth trastuzumab SC administration at Cycle 17 (cycle length=21 days)
Participant-reported Severity of Symptoms as Assessed by Monroe Dunaway Anderson Symptom Inventory (MDASI) Questionnaire
MDASI questionnaire is used to rate the severity of 13 core items (pain, fatigue, nausea, vomiting, disturbed sleep, distress, shortness of breath, memory difficulties, lack of appetite, drowsiness, dry mouth, sadness, numbness or tingling). Participants were asked to rate the severity of each symptom "at its worst" using 0-10 numerical rating scales with 0 = "not present" and 10 = "as bad as you can imagine." Total score was summed and ranged from 0 to 130, with lower scores indicating better outcome.
Time frame: Prior (0 hours) to Cycles 7, 10, 13, 16 (Each cycle=21 days)
Participant-reported Interference of Symptoms With Life as Assessed by MDASI Questionnaire
MDASI questionnaire is used to rate the interference of symptoms. The measure includes 6 symptom interference items which ask how much all symptoms, interfere with domains (general activity, mood, work, relations with others, walking, and enjoyment of life). Each items were rated on a 0-10 scale (0 = "did not interfere"; 10 = "interfered completely"). Lower scores indicating better outcome. Total score was summed and ranged from 0 to 50, with lower scores indicating better outcome.
Time frame: Prior (0 hours) to Cycles 7, 10, 13, 16 (Each cycle=21 days)
Number of Participants With Modalities Assessed Using Patient Experience Questionnaires (PEX) - Part 1:In-Hospital
PEX-Part 1 questionnaire contains 25 items to assess participant's experience on use of trastuzumab at hospital.1.Place of treatment? 2.Was it same place as for chemotherapy? 3.How long did it take to travel there? 4.How easy was travel? 5.Company required for travelling? 6.Was travelling cost a problem? 7.Considering all these,was travelling for treatment overall a problem? 8.How helpful were nursing/medical staff? 9.How pleasant was place of study? 10.How was IV treatment given? 11.If Venous Access Device(VAD),what was it? 12.Did hospital staff have difficulty inserting cannula? 13.Time for cannulation? 14.How painful was IV? 15.How much time to access port/line usually take? 16.How painful was it? 17.Time for IV sessions? 18.Anxiety level while IV treatment? 19.How would you describe IV sessions? 20.Did hospital staff have difficulty giving SC? 21.Time for SC? 22.How painful was SC? 23.Time for SC sessions? 24.Anxiety level while SC treatment? 25.How would you describe SC sessions?
Time frame: Prior (0 hours) to Cycle 12 (cycle length=21 days)
Number of Participants With Modalities Assessed Using PEX - Part 2: At Home
PEX - Part 2 questionnaire contains 6 items to assess the participant's experience on the use of trastuzumab SC vials at home.Participants answered the following questions: 1. Did the nursing staff ever have any difficulty giving the trastuzumab injection SC? 2. How many minutes did the injection (it) usually take? 3. How painful was this usually? 4. How long did the SC sessions usually last from arrival until departure of the nurse? 5. How anxious did having the SC treatment make you feel? 6. In general how would you describe these SC treatment sessions at home?
Time frame: 1 month after end of treatment (up to 10 months)
Number of Health Care Professionals With Modalities Assessed Using Health Care Professional Questionnaire (HCPEX-1)
HCPEX-1 questionnaire is used to assess health care professional's overall satisfaction and perceived time savings with trastuzumab SC vial in the hospital. The HCPEX-1 questionnaire (19 questions) was completed by the health care professionals administering the trastuzumab IV and SC in the hospital after at least 3 participants had completed the in-hospital part of the study.
Time frame: Prior (0 hours) to Cycle 12 (cycle length=21 days)
Disease-Free Survival (DFS) as Assessed by Routine Clinical, Radiological and Laboratory Criteria
DFS was defined as time from first study drug administration (i.e. Day 1 of Cycle 7) to local, regional or distant recurrence, contralateral breast cancer or death from any cause (whichever occurred first). Diagnosis of breast cancer relapse was made based on routine clinical, radiological and laboratory criteria. Acceptable methods of confirmation of recurrence included radiology, computerized tomography (CT) scan, brain scan, ultrasound, or cytology, as per local practice. In case of uncertainly, disease relapse was to be confirmed by histological or cytological examination of a suspicious lesion, if possible.
Time frame: From start of treatment up to 45 months
| Milestone | Trastuzumab | Health Care Professionals |
|---|---|---|
| Started | 102 | 21 |
| Received at least 1 dose of study drug | 101 | 0 |
| Completed | 70 | 21 |
| Not completed | 32 | 0 |
| Withdrew: Administrative/other | 1 | 0 |
| Withdrew: Adverse event/intercurrent illness | 4 | 0 |
| Withdrew: Disease progression/recurrence | 4 | 0 |
| Withdrew: Withdrawal by subject | 15 | 0 |
| Withdrew: Failure to return | 3 | 0 |
| Withdrew: Recurrence of disease | 1 | 0 |
| Withdrew: Progression of disease | 2 | 0 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Did not cooperate | 1 | 0 |
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs included both serious and non- serious AEs. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. An emergent AE was defined as occurring within 35 days after last treatment administration.
| percentage of participants | Trastuzumab |
|---|---|
| Emergent AEs | 90.1 |
| Emergent SAEs | 7.9 |
PSQ1 is a quality of care questionnaire containing 14 questions each of Sections A and B, with a total of 28 questions categorized on the opinion of participants about the clinicians, opinion of participants about the other staff and other questions. Responses to questions with section A (except question 11) were categorized to "not at all", "to a small extent", "to a moderate extent", "to a large extent", "to a very large extent", "Not applicable" and "missing". Responses to questions with section B were categorized to "Not important", "a little important", "important", "very important", "of utmost importance", "not applicable" and "missing". Responses to question 11 with section A were categorized to "Yes, but not long", "yes, quite long", "yes, much long" and "missing". Participant experience with the treatment provided during the in-hospital part of the study was evaluated with PSQ1 questionnaire completed by the participant prior to the first dose of trastuzumab SC at home.
| participants | Trastuzumab |
|---|---|
| 1a:Clinician Communication-Not at all | 0 |
| 1a:Clinician Communication-To a small extent | 4 |
| 1a:Clinician Communication-To a moderate extent | 8 |
| 1a:Clinician Communication-To a large extent | 22 |
| 1a:Clinician Communication-To a very large extent | 49 |
| 1a:Clinician Communication-Not applicable | 0 |
| 1a:Clinician Communication-Missing | 3 |
| 1b:Importance-Not important | 1 |
| 1b:Importance-A little important | 3 |
| 1b:Importance-Important | 19 |
| 1b:Importance-Very important | 40 |
| 1b:Importance-Of utmost importance | 21 |
| 1b:Importance-Not applicable | 0 |
| 1b:Importance-Missing | 2 |
| 2a:Confidence in clinicians-Not at all | 0 |
| 2a:Confidence in clinicians-To a small extent | 0 |
| 2a:Confidence in clinicians-To a moderate extent | 5 |
| 2a:Confidence in clinicians-To a large extent | 23 |
| 2a:Confidence in clinicians-To a very large extent | 56 |
| 2a:Confidence in clinicians-Not Applicable | 0 |
| 2a:Confidence in clinicians-Missing | 2 |
| 2b:Importance-Not important | 0 |
| 2b:Importance-A little important | 1 |
| 2b:Importance-Important | 13 |
| 2b:Importance-Very important | 44 |
| 2b:Importance-Of utmost importance | 25 |
| 2b:Importance-Not applicable | 0 |
| 2b:Importance-Missing | 3 |
| 3a:Clinicians cared about you-Not at all | 2 |
| 3a:Clinicians cared about you-To a small extent | 1 |
| 3a:Clinicians cared about you-To a moderate extent | 6 |
| 3a:Clinicians cared about you-To a large extent | 24 |
| 3a:Clinicians cared about you-To very large extent | 51 |
| 3a:Clinicians cared about you-Not applicable | 0 |
| 3a:Clinicians cared about you-Missing | 2 |
| 3b:Importance-Not important | 0 |
| 3b:Importance-A little important | 2 |
| 3b:Importance-Important | 16 |
| 3b:Importance-Very important | 47 |
| 3b:Importance-Of utmost importance | 18 |
| 3b:Importance-Not applicable | 0 |
| 3b:Importance-Missing | 3 |
| 4a:Clinicians interested-Not at all | 0 |
| 4a:Clinicians interested-To a small extent) | 2 |
| 4a:Clinicians interested-To a moderate extent | 12 |
| 4a:Clinicians interested-To a large extent | 29 |
| 4a:Clinicians interested-To a very large extent | 40 |
| 4a:Clinicians interested-Not applicable | 1 |
| 4a:Clinicians interested-Missing | 2 |
| 4b:Importance-Not important | 0 |
| 4b:Importance-A little important | 2 |
| 4b:Importance-Important | 15 |
| 4b:Importance-Very important | 51 |
| 4b:Importance-Of utmost importance | 15 |
| 4b:Importance-Not applicable | 0 |
| 4b:Importance-Missing | 3 |
| 5a:Time with clinicians-Not at all | 1 |
| 5a:Time with clinicians-To small extent | 4 |
| 5a:Time with clinicians-To a moderate extent | 12 |
| 5a:Time with clinicians-To a large extent | 26 |
| 5a:Time with clinician-To a very large extent | 39 |
| 5a:Time with clinicians-Not applicable | 1 |
| 5a:Time with clinicians-Missing | 3 |
| 5b:Importance-Not important | 0 |
| 5b:Importance-A little important | 2 |
| 5b:Importance-Important | 21 |
| 5b:Importance-Very important | 45 |
| 5b:Importance-Of utmost importance | 14 |
| 5b:Importance-Not applicable | 0 |
| 5b:Importance-Missing | 4 |
| 6a:Nurses communication-Not at all | 0 |
| 6a:Nurses communication-To a small extent | 1 |
| 6a:Nurses communication-To a moderate extent | 4 |
| 6a:Nurses communication-To a large extent | 19 |
| 6a:Nurses communication-To a very large extent | 60 |
| 6a:Nurses communication-Not Applicable | 0 |
| 6a:Nurses communication-Missing | 2 |
| 6b:Importance-Not important | 1 |
| 6b:Importance-A little important | 4 |
| 6b:Importance-Important | 18 |
| 6b:Importance-Very important | 44 |
| 6b:Importance-Of utmost importance | 16 |
| 6b:Importance-Not applicable | 0 |
| 6b:Importance-Missing | 3 |
| 7a:Confidence in nurses-Not at all | 0 |
| 7a:Confidence in nurses-To a small extent | 0 |
| 7a:Confidence in nurses-To a moderate extent | 4 |
| 7a:Confidence in nurses-To a large extent | 19 |
| 7a:Confidence in nurses-To a very large extent | 61 |
| 7a:Confidence in nurses-Not Applicable | 0 |
| 7a:Confidence in nurses-Missing | 2 |
| 7b:Importance-Not important | 0 |
| 7b:Importance-A little important | 1 |
| 7b:Importance-Important | 17 |
| 7b:Importance-Very important | 46 |
| 7b:Importance-Of utmost importance | 19 |
| 7b:Importance-Not applicable | 0 |
| 7b:Importance-Missing | 3 |
| 8a:Nurses cared about you-Not at all | 1 |
| 8a:Nurses cared about you-To a small extent | 2 |
| 8a:Nurses cared about you-To a moderate extent | 4 |
| 8a:Nurses cared about you-To a large extent | 25 |
| 8a:Nurses cared about you-To a very large extent | 52 |
| 8a:Nurses cared about you-Not Applicable | 0 |
| 8a:Nurses cared about you-Missing | 2 |
| 8b:Importance-Not important | 0 |
| 8b:Importance-A little important | 3 |
| 8b:Importance-Important | 22 |
| 8b:Importance-Very important | 41 |
| 8b:Importance-Of utmost importance | 17 |
| 8b:Importance-Not applicable | 0 |
| 8b:Importance-Missing | 3 |
| 9a:Nurses interested-Not at all | 0 |
| 9a:Nurses interested-To a small extent | 3 |
| 9a:Nurses interested-To a moderate extent | 3 |
| 9a:Nurses interested-To a large extent | 22 |
| 9a:Nurses interested-To a very large extent | 56 |
| 9a:Nurses interested-Not Applicable | 0 |
| 9a:Nurses interested-Missing | 2 |
| 9b:Importance-Not important | 0 |
| 9b:Importance-A little important | 5 |
| 9b:Importance-Important | 22 |
| 9b:Importance-Very important | 41 |
| 9b:Importance-Of utmost importance | 14 |
| 9b:Importance-Not applicable | 0 |
| 9b:Importance-Missing | 4 |
| 10a:Time with nurses-Not at all | 0 |
| 10a:Time with nurses-To a small extent | 4 |
| 10a:Time with nurses-To a moderate extent | 10 |
| 10a:Time with nurses-To a large extent | 20 |
| 10a:Time with nurses-To a very large extent | 49 |
| 10a:Time with nurses-Not Applicable | 1 |
| 10a:Time with nurses-Missing | 2 |
| 10b:Importance-Not important | 0 |
| 10b:Importance-A little important | 5 |
| 10b:Importance-Important | 21 |
| 10b:Importance-Very important | 40 |
| 10b:Importance-Of utmost importance | 15 |
| 10b:Importance-Not applicable | 0 |
| 10b:Importance-Missing | 5 |
| 11a:Waited for hospital admission-No | 24 |
| 11aWaited for hospital admission-Yes, but not long | 34 |
| 11a:Waited for hospital admission-Yes, quite long | 20 |
| 11a:Waited for hospital admission-Yes, much long | 4 |
| 11a:Waited for hospital admission-Missing | 4 |
| 11b:Importance-Not important | 5 |
| 11b:Importance-A little important | 12 |
| 11b:Importance-Important | 28 |
| 11b:Importance-Very important | 24 |
| 11b:Importance-Of utmost importance | 12 |
| 11b:Importance-Not applicable | 0 |
| 11b:Importance-Missing | 5 |
| 12a:Clinic equipment good order-Not at all | 0 |
| 12a:Clinic equipment good order-To a small extent | 1 |
| 12a:Clinic equipment good order-To moderate extent | 3 |
| 12a:Clinic equipment good order-To a large extent | 34 |
| 12aClinic equipment good order-To very large exten | 46 |
| 12a:Clinic equipment good order-Not applicable | 0 |
| 12a:Clinic equipment in good order-Missing | 2 |
| 12b:Importance-Not important | 0 |
| 12b:Importance-A little important | 0 |
| 12b:Importance-Important | 22 |
| 12b:Importance-Very important | 41 |
| 12b:Importance-Of utmost importance | 20 |
| 12b:Importance-Not applicable | 0 |
| 12b:Importance-Missing | 3 |
| 13a:Clinic otherwise good order-Not at all | 0 |
| 13a:Clinic otherwise good order-To a small extent | 1 |
| 13a:Clinic otherwise good order-To moderate extent | 5 |
| 13a:Clinic otherwise good order-To a large extent | 32 |
| 13aClinic otherwise good order- Very large extent | 45 |
| 13a:Clinic otherwise good order-Not Applicable | 0 |
| 13a:Clinic otherwise good order-Missing | 3 |
| 13b:Importance-Not important | 0 |
| 13b:Importance-A little important | 2 |
| 13b:Importance-Important | 23 |
| 13b:Importance-Very important | 39 |
| 13b:Importance-Of utmost importance | 18 |
| 13b:Importance-Not applicable | 0 |
| 13b:Importance-Missing | 4 |
| 14a:Satisfactory treatment-Not at all | 0 |
| 14a:Satisfactory treatment-To a small extent | 0 |
| 14a:Satisfactory treatment-To a moderate extent | 1 |
| 14a:Satisfactory treatment-To a large extent | 18 |
| 14a:Satisfactory treatment-To a very large extent | 65 |
| 14a:Satisfactory treatment-Not Applicable | 0 |
| 14a:Satisfactory treatment-Missing | 2 |
| 14b:Importance-Not important | 0 |
| 14b:Importance-A little important | 3 |
| 14b:Importance-Important | 12 |
| 14b:Importance-Very important | 43 |
| 14b:Importance-Of utmost importance | 25 |
| 14b:Importance-Not applicable | 0 |
| 14b:Importance-Missing | 3 |
PSQ2 is a quality of care questionnaire containing 13 questions each of Sections A and B, with a total of 26 questions categorized on the opinion of participants about the clinicians, opinion of participant about the other staff and other questions. Responses to questions with section A were categorized to "Not at all", "To a small extent", "to a moderate extent", "to a large extent", "to a very large extent", "Not applicable" and "missing". Responses to questions with section B were categorized to "Not important", "a little important", "important", "very important", "of utmost importance", "not applicable" and "missing". Participant experience with the treatment provided during the at-home part of the study was evaluated with the PSQ2 questionnaire completed by the participant prior to the fifth dose of trastuzumab SC at home.
| participants | Trastuzumab |
|---|---|
| 1a:Clinicians communication-Not at all | 0 |
| 1a:Clinicians communication-To a small extent | 3 |
| 1a:Clinicians communication-To a moderate extent | 8 |
| 1a:Clinicians communication-To a large extent | 28 |
| 1a:Clinicians communication-To a very large extent | 34 |
| 1a:Clinicians communication-Not Applicable | 7 |
| 1a:Clinicians communication-Missing | 3 |
| 1b:Importance-Not important | 2 |
| 1b:Importance-A little important | 0 |
| 1b:Importance-Important | 20 |
| 1b:Importance-Very important | 37 |
| 1b:Importance-Of utmost importance | 16 |
| 1b:Importance-Not applicable | 0 |
| 1b:Importance-Missing | 8 |
| 2a:Confidence in the clinicians-Not at all | 0 |
| 2a:Confidence in the clinicians-To a small extent | 1 |
| 2a:Confidence in the clinicians-To moderate extent | 2 |
| 2a:Confidence in the clinicians-To a large extent | 20 |
| 2a:Confidence in clinician-To very large extent | 51 |
| 2a:Confidence in the clinicians-Not applicable | 5 |
| 2a:Confidence in the clinicians-Missing | 4 |
| 2b:Importance-Not important | 0 |
| 2b:Importance-A little important | 0 |
| 2b:Importance-Important | 14 |
| 2b:Importance-Very important | 38 |
| 2b:Importance-Of utmost importance | 23 |
| 2b:Importance-Not applicable | 0 |
| 2b:Importance-Missing | 8 |
| 3a:Clinicians cared about you-Not at all | 2 |
| 3a:Clinicians cared about you-To a small extent | 1 |
| 3a:Clinicians cared about you-To a moderate extent | 6 |
| 3a:Clinicians cared about you-To a large extent | 22 |
| 3a:Clinician cared about you-To very large extent | 42 |
| 3a:Clinicians cared about you-Not Applicable | 6 |
| 3a:Clinicians cared about you-Missing | 4 |
| 3b:Importance-Not important | 0 |
| 3b:Importance-A little important | 1 |
| 3b:Importance-Important | 20 |
| 3b:Importance-Very important | 34 |
| 3b:Importance-Of utmost importance | 20 |
| 3b:Importance-Not applicable | 0 |
| 3b:Importance-Missing | 8 |
| 4a:Clinicians interested-Not at all | 0 |
| 4a:Clinicians interested-To a small extent | 1 |
| 4a:Clinicians interested-To a moderate extent | 9 |
| 4a:Clinicians interested-To a large extent | 27 |
| 4a:Clinicians interested-To a very large extent | 36 |
| 4a:Clinicians interested-Not applicable | 6 |
| 4a:Clinicians interested-Missing | 4 |
| 4b:Importance-Not important | 0 |
| 4b:Importance-A little important | 1 |
| 4b:Importance-Important | 19 |
| 4b:Importance-Very important | 34 |
| 4b:Importance-Of utmost importance | 21 |
| 4b:Importance-Not applicable | 0 |
| 4b:Importance-Missing | 8 |
| 5a:Clinicians interaction-Not at all | 1 |
| 5a:Clinicians interaction-To a small extent | 0 |
| 5a:Clinicians interaction-To moderate extent | 11 |
| 5a:Clinicians interaction-To a large extent | 31 |
| 5a:Clinicians interaction-To very large extent | 30 |
| 5a:Clinicians interaction-Not Applicable | 6 |
| 5a:Clinicians interaction-Missing | 4 |
| 5b:Importance-Not important | 0 |
| 5b:Importance-A little important | 0 |
| 5b:Importance-Important | 22 |
| 5b:Importance-Very important | 35 |
| 5b:Importance-Of utmost importance | 18 |
| 5b:Importance-Not applicable | 0 |
| 5b:Importance-Missing | 8 |
| 6a:Nurses communication-Not at all | 0 |
| 6a:Nurses communication-To a small extent | 1 |
| 6a:Nurses communication-To a moderate extent | 1 |
| 6a:Nurses communication-To a large extent | 17 |
| 6a:Nurses communication-To a very large extent | 62 |
| 6a:Nurses communication-Not applicable | 1 |
| 6a:Nurses communication-Missing | 1 |
| 6b:Importance-Not important | 0 |
| 6b:Importance-A little important | 0 |
| 6b:Importance-Important | 22 |
| 6b:Importance-Very important | 39 |
| 6b:Importance-Of utmost importance | 21 |
| 6b:Importance-Not applicable | 0 |
| 6b:Importance-Missing | 1 |
| 7a:Confidence in the nurses-Not at all | 0 |
| 7a:Confidence in the nurses-To a small extent | 0 |
| 7a:Confidence in the nurses-To a moderate extent | 1 |
| 7a:Confidence in the nurses-To a large extent | 23 |
| 7a:Confidence in the nurses-To a very large extent | 58 |
| 7a:Confidence in the nurses-Not applicable | 0 |
| 7a:Confidence in the nurses-Missing | 1 |
| 7b:Importance-Not important | 0 |
| 7b:Importance-A little important | 1 |
| 7b:Importance-Important | 17 |
| 7b:Importance-Very important | 41 |
| 7b:Importance-Of utmost importance | 23 |
| 7b:Importance-Not applicable | 0 |
| 7b:Importance-Missing | 1 |
| 8a:Nurses cared about you-Not at all | 0 |
| 8a:Nurses cared about you-To a small extent | 0 |
| 8a:Nurses cared about you-To a moderate extent | 2 |
| 8a:Nurses cared about you-To a large extent | 23 |
| 8a:Nurses cared about you-To a very large extent | 57 |
| 8a:Nurses cared about you-Not applicable | 0 |
| 8a:Nurses cared about you-Missing | 1 |
| 8b:Importance-Not important | 0 |
| 8b:Importance-A little important | 1 |
| 8b:Importance-Important | 22 |
| 8b:Importance-Very important | 38 |
| 8b:Importance-Of utmost importance | 20 |
| 8b:Importance-Not applicable | 0 |
| 8b:Importance-Missing | 2 |
| 9a:Nurses interested-Not at all | 0 |
| 9a:Nurses interested-To a small extent | 0 |
| 9a:Nurses interested-To a moderate extent | 4 |
| 9a:Nurses interested-To a large extent | 29 |
| 9a:Nurses interested-To a very large extent | 49 |
| 9a:Nurses interested-Not applicable | 0 |
| 9a:Nurses interested-Missing | 1 |
| 9b:Importance-Not important | 0 |
| 9b:Importance-A little important | 2 |
| 9b:Importance-Important | 27 |
| 9b:Importance-Very important | 34 |
| 9b:Importance-Of utmost importance | 18 |
| 9b:Importance-Not applicable | 0 |
| 9b:Importance-Missing | 2 |
| 10a:Nurses interaction-Not at all | 0 |
| 10a:Nurses interaction-To a small extent | 1 |
| 10a:Nurses interaction-To a moderate extent | 6 |
| 10a:Nurses interaction-To a large extent | 26 |
| 10a:Nurses interaction-To a very large extent | 49 |
| 10a:Nurses interaction-Not applicable | 0 |
| 10a:Nurses interaction-Missing | 1 |
| 10a:Importance-Not important | 0 |
| 10a:Importance-A little important | 3 |
| 10b:Importance-Important | 27 |
| 10b:Importance-Very important | 34 |
| 10b:Importance-Of utmost importance | 17 |
| 10b:Importance-Not applicable | 0 |
| 10b:Importance-Missing | 2 |
| 11a:Nurses equipment good order-Not at all | 0 |
| 11a:Nurses equipment good order-To a small extent | 0 |
| 11a:Nurses equipment good order-To moderate extent | 2 |
| 11a:Nurses equipment good order-To a large extent | 27 |
| 11a:Nurse equipment good order-To verylarge extent | 51 |
| 11a:Nurses equipment good order-Not applicable | 1 |
| 11a:Nurses equipment good order-Missing | 2 |
| 11b:Importance-Not important | 1 |
| 11b:Importance-A little important | 2 |
| 11b:Importance-Important | 21 |
| 11b:Importance-Very important | 41 |
| 11b:Importance-Of utmost importance | 17 |
| 11b:Importance-Not applicable | 0 |
| 11b:Importance-Missing | 1 |
| 12a:Satisfaction-Not at all | 0 |
| 12a:Satisfaction-To a small extent | 0 |
| 12a:Satisfaction-To a moderate extent | 0 |
| 12a:Satisfaction-To a large extent | 14 |
| 12a:Satisfaction-To a very large extent | 67 |
| 12a:Satisfaction-Not applicable | 0 |
| 12a:Satisfaction-Missing | 2 |
| 12a:Importance-Not important | 0 |
| 12a:Importance-A little important | 0 |
| 12b:Importance-Important | 18 |
| 12b:Importance-Very important | 42 |
| 12b:Importance-Of utmost importance | 22 |
| 12b:Importance-Not applicable | 0 |
| 12b:Importance-Missing | 1 |
| 13a:Care benefit at home-Not at all | 0 |
| 13a:Care benefit at home-To a small extent | 0 |
| 13a:Care benefit at home-To moderate extent | 0 |
| 13a:Care benefit at home-To a large extent | 18 |
| 13a:Care benefit at home-To very large extent | 63 |
| 13a:Care benefit at home-Not applicable | 0 |
| 13a:Care benefit at home-Missing | 2 |
| 13b:Importance-Not important | 0 |
| 13b:Importance-A little important | 1 |
| 13b:Importance-Important | 19 |
| 13b:Importance-Very important | 41 |
| 13b:Importance-Of utmost importance | 21 |
| 13b:Importance-Not applicable | 0 |
| 13b:Importance-Missing | 1 |
MDASI questionnaire is used to rate the severity of 13 core items (pain, fatigue, nausea, vomiting, disturbed sleep, distress, shortness of breath, memory difficulties, lack of appetite, drowsiness, dry mouth, sadness, numbness or tingling). Participants were asked to rate the severity of each symptom "at its worst" using 0-10 numerical rating scales with 0 = "not present" and 10 = "as bad as you can imagine." Total score was summed and ranged from 0 to 130, with lower scores indicating better outcome.
| units on a scale | Trastuzumab |
|---|---|
| Pain- IV (Hospital) - Cycle 7 | 1.79 ± 2.51 |
| Fatigue- IV (Hospital) - Cycle 7 | 3.76 ± 2.69 |
| Nausea- IV (Hospital) - Cycle 7 | 0.82 ± 1.96 |
| Disturbed Sleep- IV (Hospital) - Cycle 7 | 3.01 ± 2.89 |
| Distressed- IV (Hospital) - Cycle 7 | 1.99 ± 2.27 |
| Breath shortness- IV (Hospital) - Cycle 7 | 1.59 ± 2.13 |
| Remembering things-IV (Hospital) - Cycle 7 | 1.97 ± 2.32 |
| Lack of appetite-IV (Hospital) - Cycle 7 | 0.85 ± 1.80 |
| Drowsy- IV (Hospital) - Cycle 7 | 2.25 ± 2.54 |
| Dry mouth- IV (Hospital) - Cycle 7 | 1.89 ± 2.51 |
| Feeling sad- IV (Hospital) - Cycle 7 | 1.90 ± 2.26 |
| Vomiting- IV (Hospital) - Cycle 7 | 0.34 ± 1.31 |
| Numbness- IV (Hospital) - Cycle 7 | 3.01 ± 3.20 |
| Pain- SC (Hospital) - Cycle 10 | 1.81 ± 2.14 |
| Fatigue- SC (Hospital) - Cycle 10 | 3.35 ± 2.45 |
| Nausea- SC (Hospital) - Cycle 10 | 0.61 ± 1.41 |
| Disturbed Sleep- SC (Hospital) - Cycle 10 | 2.70 ± 2.86 |
| Distressed- SC (Hospital) - Cycle 10 | 2.10 ± 2.57 |
| Breath shortness- SC (Hospital) - Cycle 10 | 1.29 ± 1.88 |
| Remembering thing- SC (Hospital) - Cycle 10 | 2.01 ± 2.21 |
| Lack of appetite- SC (Hospital) - Cycle 10 | 0.81 ± 1.67 |
| Drowsy- SC (Hospital) - Cycle 10 | 2.32 ± 2.52 |
| Dry mouth- SC (Hospital) - Cycle 10 | 1.42 ± 2.06 |
| Feeling sad- SC (Hospital) - Cycle 10 | 1.87 ± 2.38 |
| Vomiting- SC (Hospital) - Cycle 10 | 0.26 ± 0.81 |
| Numbness- SC (Hospital) - Cycle 10 | 2.73 ± 2.76 |
| Pain- SC (Home) - Cycle 13 | 1.54 ± 2.33 |
| Fatigue- SC (Home) - Cycle 13 | 3.42 ± 2.27 |
| Nausea- SC (Home) - Cycle 13 | 0.45 ± 1.25 |
| Disturbed Sleep- SC (Home) - Cycle 13 | 2.63 ± 2.50 |
| Distressed- SC (Home) - Cycle 13 | 1.81 ± 2.27 |
| Breath shortness- SC (Home) - Cycle 13 | 1.28 ± 2.06 |
| Remembering things- SC (Home) - Cycle 13 | 1.95 ± 2.07 |
| Lack of appetite- SC (Home) - Cycle 13 | 0.43 ± 1.29 |
| Drowsy- SC (Home) - Cycle 13 | 1.87 ± 2.26 |
| Dry mouth- SC (Home) - Cycle 13 | 1.57 ± 2.30 |
| Feeling sad- SC (Home) - Cycle 13 | 1.80 ± 2.32 |
| Vomiting- SC (Home) - Cycle 13 | 0.22 ± 1.16 |
| Numbness- SC (Home) - Cycle 13 | 2.51 ± 2.64 |
| Pain- SC (Home) - Cycle 16 | 1.49 ± 2.06 |
| Fatigue- SC (Home) - Cycle 16 | 2.79 ± 2.05 |
| Nausea- SC (Home) - Cycle 16 | 0.57 ± 1.35 |
| Disturbed Sleep- SC (Home) - Cycle 16 | 2.11 ± 2.28 |
| Distressed- SC (Home) - Cycle 16 | 2.01 ± 2.33 |
| Breath shortness- SC (Home) - Cycle 16 | 1.38 ± 2.05 |
| Remembering things- SC (Home) - Cycle 16 | 2.14 ± 2.12 |
| Lack of appetite- SC (Home) - Cycle 16 | 0.71 ± 1.63 |
| Drowsy- SC (Home) - Cycle 16 | 1.74 ± 2.01 |
| Dry mouth- SC (Home) - Cycle 16 | 1.39 ± 1.93 |
| Feeling sad- SC (Home) - Cycle 16 | 1.98 ± 2.24 |
| Vomiting- SC (Home) - Cycle 16 | 0.14 ± 0.61 |
| Numbness- SC (Home) - Cycle 16 | 2.00 ± 2.29 |
MDASI questionnaire is used to rate the interference of symptoms. The measure includes 6 symptom interference items which ask how much all symptoms, interfere with domains (general activity, mood, work, relations with others, walking, and enjoyment of life). Each items were rated on a 0-10 scale (0 = "did not interfere"; 10 = "interfered completely"). Lower scores indicating better outcome. Total score was summed and ranged from 0 to 50, with lower scores indicating better outcome.
| units on a scale | Trastuzumab |
|---|---|
| General activity- IV (Hospital) - Cycle 7 | 2.77 ± 2.73 |
| Mood- IV (Hospital) - Cycle 7 | 2.11 ± 2.13 |
| Work- IV (Hospital) - Cycle 7 | 3.22 ± 2.86 |
| Relations- IV (Hospital) - Cycle 7 | 1.54 ± 2.13 |
| Walking- IV (Hospital) - Cycle 7 | 3.34 ± 3.06 |
| Enjoyment of life- IV (Hospital) - Cycle 7 | 2.51 ± 2.55 |
| General activity- SC (Hospital) - Cycle 10 | 2.24 ± 2.35 |
| Mood- SC (Hospital) - Cycle 10 | 1.92 ± 2.28 |
| Work- SC (Hospital) - Cycle 10 | 2.63 ± 2.71 |
| Relations- SC (Hospital) - Cycle 10 | 1.48 ± 2.30 |
| Walking- SC (Hospital) - Cycle 10 | 2.38 ± 2.69 |
| Enjoyment of life- SC (Hospital) - Cycle 10 | 2.21 ± 2.67 |
| General activity- SC (Home) - Cycle 13 | 2.27 ± 2.48 |
| Mood- SC (Home) - Cycle 13 | 1.81 ± 2.28 |
| Work- SC (Home) - Cycle 13 | 2.35 ± 2.26 |
| Relations- SC (Home) - Cycle 13 | 1.13 ± 1.93 |
| Walking- SC (Home) - Cycle 13 | 2.13 ± 2.79 |
| Enjoyment of life- SC (Home) - Cycle 13 | 2.06 ± 2.66 |
| General activity- SC (Home) - Cycle 16 | 1.84 ± 2.12 |
| Mood- SC (Home) - Cycle 16 | 1.76 ± 2.13 |
| Work- SC (Home) - Cycle 16 | 2.00 ± 2.21 |
| Relations- SC (Home) - Cycle 16 | 1.02 ± 1.85 |
| Walking- SC (Home) - Cycle 16 | 1.67 ± 2.41 |
| Enjoyment of life- SC (Home) - Cycle 16 | 1.90 ± 2.37 |
PEX-Part 1 questionnaire contains 25 items to assess participant's experience on use of trastuzumab at hospital.1.Place of treatment? 2.Was it same place as for chemotherapy? 3.How long did it take to travel there? 4.How easy was travel? 5.Company required for travelling? 6.Was travelling cost a problem? 7.Considering all these,was travelling for treatment overall a problem? 8.How helpful were nursing/medical staff? 9.How pleasant was place of study? 10.How was IV treatment given? 11.If Venous Access Device(VAD),what was it? 12.Did hospital staff have difficulty inserting cannula? 13.Time for cannulation? 14.How painful was IV? 15.How much time to access port/line usually take? 16.How painful was it? 17.Time for IV sessions? 18.Anxiety level while IV treatment? 19.How would you describe IV sessions? 20.Did hospital staff have difficulty giving SC? 21.Time for SC? 22.How painful was SC? 23.Time for SC sessions? 24.Anxiety level while SC treatment? 25.How would you describe SC sessions?
| participants | Trastuzumab |
|---|---|
| Place of study treatment: hospital chemo dept | 87 |
| Place of study treatment: other chemo clinic | 0 |
| Place of study treatment: Doctor's office | 0 |
| Place of study treatment: other | 0 |
| Place of study treatment: missing | 15 |
| Same place as for your chemotherapy: yes | 87 |
| Same place as for your chemotherapy: no | 0 |
| Same place as for your chemotherapy: missing | 15 |
| Travel time: <1 hour | 70 |
| Travel time: 1 to 2 hours | 12 |
| Travel time: >2 hours | 5 |
| Travel time: missing | 15 |
| Travelling easy: not at all | 9 |
| Travelling easy: fairly | 44 |
| Travelling easy: very | 34 |
| Travelling easy: missing | 15 |
| Company required for travelling: always | 32 |
| Company required for travelling: sometimes | 19 |
| Company required for travelling: never | 36 |
| Company required for travelling: missing | 15 |
| Travelling cost, a problem: not at all | 60 |
| Travelling cost, a problem: fairly | 23 |
| Travelling cost, a problem: very | 4 |
| Travelling cost, a problem: missing | 15 |
| Travelling overall, a problem: yes | 18 |
| Travelling overall, a problem: no | 69 |
| Travelling overall, a problem: missing | 15 |
| Nursing and medical staff helpful: not at all | 0 |
| Nursing and medical staff helpful: fairly | 15 |
| Nursing and medical staff helpful: very | 72 |
| Nursing and medical staff helpful: missing | 15 |
| Pleasant place of treatment: not at all | 3 |
| Pleasant place of treatment: fairly | 39 |
| Pleasant place of treatment: very | 44 |
| Pleasant place of treatment: missing | 16 |
| IV administration method: cannula/needle | 34 |
| IV administration method:Venous Access Device(VAD) | 47 |
| IV administration method: both | 6 |
| IV administration method: missing | 15 |
| VAD: Hickman | 0 |
| VAD: peripherally inserted central catheters | 5 |
| VAD: port-a-cath | 47 |
| VAD: other | 9 |
| VAD: missing | 41 |
| Difficulty inserting the cannula: very often | 5 |
| Difficulty inserting the cannula: sometimes | 15 |
| Difficulty inserting the cannula: never | 22 |
| Difficulty inserting the cannula: missing | 60 |
| Time for insertion of the cannula: <5 minutes | 30 |
| Time for insertion of the cannula: 6-10 minutes | 7 |
| Time for insertion of the cannula: 11-15 minutes | 1 |
| Time for insertion of the cannula:16-20 minutes | 0 |
| Time for insertion of the cannula: >20 minutes | 2 |
| Time for insertion of the cannula: missing | 62 |
| Cannulation painfull: not at all | 20 |
| Cannulation painfull: fairly | 18 |
| Cannulation painfull: very | 4 |
| Cannulation painfull: missing | 60 |
| Time for connection to the access port: <5 minutes | 39 |
| Time for connection to access port: 6-10 minutes | 8 |
| Time for connection to access port: 11-15 minutes | 1 |
| Time for connection to access port: 16-20 minutes | 1 |
| Time for connection to access port: >20 minutes | 0 |
| Time for connection to access port: missing | 53 |
| Connection painful: not at all | 36 |
| Connection painful: fairly | 14 |
| Connection painful: very | 0 |
| Connection painful: missing | 52 |
| Time for IV session: <2 hours | 21 |
| Time for IV session: 2-3 hours | 25 |
| Time for IV session: 3-4 hours | 26 |
| Time for IV session: >4 hours | 13 |
| Time for IV session: missing | 17 |
| Anxiety during IV treatment: not at all | 64 |
| Anxiety during IV treatment: fairly | 20 |
| Anxiety during IV treatment: very | 2 |
| Anxiety during IV treatment: missing | 16 |
| General IV session: very unpleasant | 2 |
| General IV session: fairly unpleasant | 15 |
| General IV session: acceptable | 68 |
| General IV session: missing | 17 |
| Difficulty in SC injection: very often | 0 |
| Difficulty in SC injection: sometimes | 4 |
| Difficulty in SC injection: never | 82 |
| Difficulty in SC injection: missing | 16 |
| Time for SC injection: <5 minutes | 56 |
| Time for SC injection: 6-10 minutes | 26 |
| Time for SC injection: 11-15 minutes | 1 |
| Time for SC injection: 16-20 minutes | 0 |
| Time for SC injection: >20 minutes | 3 |
| Time for SC injection: missing | 16 |
| SC injection painful: not at all | 53 |
| SC injection painful: fairly | 33 |
| SC injection painful: very | 1 |
| SC injection painful: missing | 15 |
| Time for SC session: <2 hours | 46 |
| Time for SC session: 2-3 hours | 24 |
| Time for SC session: 3-4 hours | 9 |
| Time for SC session: >4 hours | 7 |
| Time for SC session: missing | 16 |
| Anxiety during SC treatment: not at all | 63 |
| Anxiety during SC treatment: fairly | 21 |
| Anxiety during SC treatment: very | 3 |
| Anxiety during SC treatment: missing | 15 |
| General SC session: very unpleasant | 0 |
| General SC session: fairly unpleasant | 7 |
| General SC session: acceptable | 79 |
| General SC session: missing | 16 |
PEX - Part 2 questionnaire contains 6 items to assess the participant's experience on the use of trastuzumab SC vials at home.Participants answered the following questions: 1. Did the nursing staff ever have any difficulty giving the trastuzumab injection SC? 2. How many minutes did the injection (it) usually take? 3. How painful was this usually? 4. How long did the SC sessions usually last from arrival until departure of the nurse? 5. How anxious did having the SC treatment make you feel? 6. In general how would you describe these SC treatment sessions at home?
| participants | Trastuzumab |
|---|---|
| Difficulty in SC administration: very often | 0 |
| Difficulty in SC administration: sometimes | 5 |
| Difficulty in SC administration: never | 77 |
| Difficulty in SC administration: missing | 20 |
| SC administration time: <5 minutes | 65 |
| SC administration time: 6-10 minutes | 17 |
| SC administration time: 11-15 minutes | 0 |
| SC administration time: 16-20 minutes | 0 |
| SC administration time: >20 minutes | 0 |
| SC administration time: missing | 20 |
| SC administration Painful: not at all | 61 |
| SC administration Painful: fairly | 20 |
| SC administration Painful: very | 0 |
| SC administration Painful: missing | 21 |
| Time for SC session: <2 hours | 82 |
| Time for SC session: 2-3 hours | 0 |
| Time for SC session: 3-4 hours | 0 |
| Time for SC session: >4 hours | 0 |
| Time for SC session: missing | 20 |
| Anxiety during SC treatment: not at all | 71 |
| Anxiety during SC treatment: fairly | 11 |
| Anxiety during SC treatment: very | 0 |
| Anxiety during SC treatment: missing | 20 |
| General SC session: very unpleasant | 3 |
| General SC session: fairly unpleasant | 0 |
| General SC session: acceptable | 79 |
| General SC session: missing | 20 |
HCPEX-1 questionnaire is used to assess health care professional's overall satisfaction and perceived time savings with trastuzumab SC vial in the hospital. The HCPEX-1 questionnaire (19 questions) was completed by the health care professionals administering the trastuzumab IV and SC in the hospital after at least 3 participants had completed the in-hospital part of the study.
| Health care professionals | Health Care Professionals |
|---|---|
| Specialty: Oncologist | 0 |
| Specialty: Gynecologist | 0 |
| Specialty: Oncologist/ Specialist Chemo Nurse | 19 |
| Specialty: Other | 2 |
| Specialty: Missing | 0 |
| Personal administration of SC: always | 6 |
| Personal administration of SC: sometimes | 15 |
| Personal administration of SC: never | 0 |
| Personal administration of SC: missing | 0 |
| Time required for SC preparation: <5 minutes | 7 |
| Time required for SC preparation: 6-10 minutes | 2 |
| Time required for SC preparation: 11-15 minutes | 1 |
| Time required for SC preparation: 16-20 minutes | 1 |
| Time required for SC preparation: >20 minutes | 1 |
| Time required for SC preparation: not sure | 9 |
| Time required for SC preparation: missing | 0 |
| Time required for SC administration: <3 minutes | 1 |
| Time required for SC administration: <5 minutes | 16 |
| Time required for SC administration: 6-15 minutes | 3 |
| Time required for SC administration: 16-30 minutes | 1 |
| Time required for SC administration: 31-60 minutes | 0 |
| Time required for SC administration: 61-90 minutes | 0 |
| Time required for SC administration: >90 minutes | 0 |
| Time required for SC administration: not sure | 0 |
| Time required for SC administration: missing | 0 |
| Time for SC session: <2 hours | 14 |
| Time for SC session: 2-3 hours | 7 |
| Time for SC session: 3-4 hours | 0 |
| Time for SC session: >4 hours | 0 |
| Time for SC session: missing | 0 |
| Reliability of SC hand held syringe: not at all | 0 |
| Reliability of SC hand held syringe: fairly | 10 |
| Reliability of SC hand held syringe: very | 11 |
| Reliability of SC hand held syringe: missing | 0 |
| Easy to administer SC hand held syringe:not at all | 0 |
| Easy to administer SC hand held syringe: fairly | 13 |
| Easy to administer SC hand held syringe: very | 8 |
| Easy to administer SC hand held syringe: missing | 0 |
| convenient method for IV treatment- cannula | 7 |
| convenient method for IV treatment- VAD | 14 |
| convenient method for IV treatment- not sure | 0 |
| convenient method for IV treatment- missing | 0 |
| Personally administer IV: always | 4 |
| Personally administer IV: sometimes | 15 |
| Personally administer IV: never | 2 |
| Personally administer IV: missing | 0 |
| Personally Cannulate: always | 5 |
| Personally Cannulate: sometimes | 10 |
| Personally Cannulate: never | 5 |
| Personally Cannulate: missing | 1 |
| Time for IV preparation: <5 minutes | 1 |
| Time for IV preparation: 6-10 minutes | 2 |
| Time for IV preparation: 11-15 minutes | 2 |
| Time for IV preparation: 16-20 minutes | 1 |
| Time for IV preparation: >20 minutes | 5 |
| Time for IV preparation: not sure | 10 |
| Time for IV preparation: missing | 0 |
| Time for cannulation: <5 minutes | 8 |
| Time for cannulation: 6-10 minutes | 4 |
| Time for cannulation: 11-15 minutes | 1 |
| Time for cannulation: 16-20 minutes | 0 |
| Time for cannulation: >20 minutes | 2 |
| Time for cannulation: not sure | 5 |
| Time for cannulation: missing | 1 |
| Time for connection: <3 minutes | 1 |
| Time for connection: <5 minutes | 3 |
| Time for connection: 6-15 minutes | 0 |
| Time for connection: 16-30 minutes | 2 |
| Time for connection: 31-60 minutes | 8 |
| Time for connection: 61-90 minutes | 5 |
| Time for connection: >90 minutes | 1 |
| Time for connection: not sure | 1 |
| Time for connection: missing | 0 |
| Time for IV session: <2 hours | 5 |
| Time for IV session: 2-3 hours | 11 |
| Time for IV session: 3-4 hours | 4 |
| Time for IV session: >4 hours | 1 |
| Time for IV session: missing | 0 |
| Anxiety during IV treatment: not at all | 14 |
| Anxiety during IV treatment: fairly | 6 |
| Anxiety during IV treatment: very | 1 |
| Anxiety during IV treatment: missing | 0 |
| Reliablily of IV treatment: not at all | 0 |
| Reliablily of IV treatment: fairly | 8 |
| Reliablily of IV treatment: very | 13 |
| Reliablily of IV treatment: missing | 0 |
| IV administration easy: not at all | 0 |
| IV administration easy: fairly | 12 |
| IV administration easy: very | 9 |
| IV administration easy: missing | 0 |
| Quickest administration: IV | 0 |
| Quickest administration: SC (handheld syringe) | 21 |
| Quickest administration: no difference | 0 |
| Quickest administration: missing | 0 |
| Require less resource: IV | 0 |
| Require less resource: SC (handheld syringe) | 21 |
| Require less resource: no difference | 0 |
| Require less resource: missing | 0 |
DFS was defined as time from first study drug administration (i.e. Day 1 of Cycle 7) to local, regional or distant recurrence, contralateral breast cancer or death from any cause (whichever occurred first). Diagnosis of breast cancer relapse was made based on routine clinical, radiological and laboratory criteria. Acceptable methods of confirmation of recurrence included radiology, computerized tomography (CT) scan, brain scan, ultrasound, or cytology, as per local practice. In case of uncertainly, disease relapse was to be confirmed by histological or cytological examination of a suspicious lesion, if possible.
| months | Trastuzumab |
|---|---|
| Disease-Free Survival (DFS) as Assessed by Routine Clinical, Radiological and Laboratory Criteria | NA (NA to NA) |
Collected over Up to 45 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Trastuzumab | 2/101 (2%) | 8/101 (7.9%) | 44/101 (43.6%) |
| Health Care Professionals | — | — | — |
| Event | Trastuzumab | Health Care Professionals |
|---|---|---|
| Ejection fraction decreasedInvestigations | 5/101 | — |
| VertigoEar and labyrinth disorders | 1/101 | — |
| Infected lymphoceleInfections and infestations | 1/101 | — |
| LymphoedemaVascular disorders | 1/101 | — |
| Event | Trastuzumab | Health Care Professionals |
|---|---|---|
| FatigueGeneral disorders | 34/101 | — |
| Injection site erythemaGeneral disorders | 14/101 | — |
| Injection site swellingGeneral disorders | 14/101 | — |
Intent-to-Treat (ITT) population included all enrolled participants. HCPs included for polling purposes. Baseline information not collected on HCPs. HCPs were not enrolled in the study.
| Age, Continuous(Years) | Trastuzumab |
|---|---|
| Mean | 54.38 ± 12.28 |
| Sex: Female, Male(Participants) | Trastuzumab |
|---|---|
| Female | 101 |
| Male | 1 |
| Race (NIH/OMB)(Participants) | Trastuzumab |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 98 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2013 to primary completion in Sep 2015, 21 months.
Results were first posted in Sep 2019, 4 years after primary completion.
Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 21 months is below that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trastuzumab